LAUSR

Ovarian cancer (OC) is one of the few malignancies in which immunotherapy with immune checkpoint inhibitors exhibits only modest activity and currently has no FDA-approved indication. Therefore, the development of strategies to improve the efficacy of immune checkpoint blockade is a high priority in this disease. Recent studies in OC models have demonstrated that PARP inhibitors (PARPi), besides their direct cytotoxic effects, exhibit antitumor immunity that occurs in a STING-dependent manner and is augmented by immune checkpoint blockade. Based on these studies, combined PARP and immune checkpoint inhibition represents an active area of clinical investigation in OC. The goal of this presentation is to outline the preclinical data behind combined PARP and immune checkpoint inhibition in OC, highlight preliminary results as well as ongoing clinical trials of PARPi/immune checkpoint inhibitor combinations in both first-line and recurrent disease, and discuss emerging biomarkers of response. Citation Format: Panagiotis A. Konstantinopoulos. Combined PARP and immune checkpoint inhibition in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr IA26.